|1.||Weiden, P L: 2 articles (10/2001 - 02/2000)|
|2.||Axworthy, D: 2 articles (04/2001 - 02/2000)|
|3.||Breitz, H B: 1 article (10/2001)|
|4.||Lin, Y: 1 article (04/2001)|
|5.||Schultz, J: 1 article (04/2001)|
|6.||Goshorn, S: 1 article (04/2001)|
|7.||Sanderson, J: 1 article (04/2001)|
|8.||Hylarides, M: 1 article (04/2001)|
|9.||Goris, M L: 1 article (02/2000)|
|10.||Weiner, L M: 1 article (02/2000)|
01/01/1992 - "In order to confirm these predictions experimentally, this study compared the relative efficacy of a pancarcinoma antibody, NR-LU-10 labeled with 186Re or 131I in 0.8-1.0 mm diameter LS174T human colon adenocarcinoma multicell spheroids. "
10/01/2001 - "Pretargeted radioimmunotherapy (PRIT) was first investigated in a series of phase I and phase II studies in patients with adenocarcinoma using a pancarcinoma antibody, NR-LU-10. "
08/01/1993 - "This prospective trial evaluated the usefulness of a new radiolabeled monoclonal antibody, NR-LU-10, as an adjunct to computed tomography by assessing its clinical applicability and accuracy in detecting malignancy in primary lung tumors and mediastinal nodes. "
04/01/2001 - "Preclinical evaluation of a humanized NR-LU-10 antibody-streptavidin fusion protein for pretargeted cancer therapy."
01/01/1998 - "Subsequent reaction with NR-LU-10 antibody Fab fragment followed by purification via QAE Sephadex anion exchange resin filter afforded 99mTc-N3S-NR-LU-10 Fab conjugate with retained immunoreactivity and effective tumor targeting properties."
06/01/1993 - "We have estimated absorbed dose to normal organs and tumors following administration of two different 186Re-labeled immunoconjugates, intact NR-LU-10 antibody and the F(ab')2 fragment of NR-CO-02. "
|3.||Lung Neoplasms (Lung Cancer)
08/01/1993 - "In 21 patients who had surgical correlation of mediastinal nodal involvement, NR-LU-10 was false-positive in 5 and false-negative in 1; results of computed tomography were false-positive in 6 and false-negative in 1. In this preliminary study, NR-LU-10 antibody scanning was safe and easily performed, it produced high-quality images of the lung and mediastinum, and it was accurate in detecting primary non-small-cell lung cancers. "
09/01/1997 - "Tc-99m nofetumomab merpentan (Verluma), consisting of a Fab fragment of the pancarcinoma murine antibody NR-LU-10, has been previously evaluated as a diagnostic imaging agent in staging patients with lung cancer. "
|4.||Colonic Neoplasms (Colon Cancer)
12/15/1997 - "In patients with lung carcinoma, technetium-99m-labeled NR-LU-10 antibody has been shown to be useful in preoperative staging. "
10/01/1993 - "Rhenium 186 was conjugated to murine monoclonal antibody NR-LU-10, which binds to a cell surface antigen present on ovarian carcinoma. "
09/15/1989 - "A mouse IgG2b anti-pan carcinoma monoclonal antibody, NR-LU-10, was shown to bind homogeneously to ascites xenografts of both ovarian and colon carcinoma. "
|3.||procaine isothiocyanate (PRIT)
|6.||Immunoglobulin G (IgG)
|7.||Surface Antigens (Surface Antigen)
|9.||technetium Tc 99m-nofetumomab merpentan (Verluma)
|2.||Heterologous Transplantation (Xenotransplantation)